Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
|
|
Bison Capital Acquisition Corp (XYN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/15/2019 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Certificate of Incorporation of the Company, effective on May 14, 2019",
"Amended and Restated Certificate of Incorporation of the Company, effective on May 15, 2019",
"Bylaws of the Company, effective as of May 15, 2019",
"Amended and Restated Registration Rights Agreement",
"Escrow Agreement",
"Form of Indemnification Agreement with each director and office",
"Insider Trading Policy",
"Resignation of Peixin Xu",
"Subsidiaries of Registrant",
"Audited Financial Statements of Xynomic Pharmaceuticals, Inc" |
|
| 09/12/2018 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger, by and among Bison Capital Acquisition Corp., Bison Capital Merger Sub Inc., Xynomic Pharmaceuticals, Inc., and Yinglin Mark Xu solely in his capacity as the Stockholder Representative",
"Voting and Support Agreement, by and among Xynomic Pharmaceuticals, Inc. and the investors party thereto",
"Form of Lock-Up Agreement to be entered into by and among Bison Capital Acquisition Corp. and the stockholders party thereto",
"Form of Amended and Restated Registration Rights Agreement to be entered into by and among Bison Capital Acquisition Corp. and the investors party thereto",
"Form of Escrow Agreement to be entered into by and among Bison Capital Acquisition Corp., Yinglin Mark Xu and Continental Stock Transfer & Trust Company",
"Form of Non-Competition Agreement to be entered into by and among Bison Capital Acquisition Corp. and the covered parties thereto",
"Form of Letter of Transmittal",
"Bison Capital Acquisition Corp. and Xynomic Pharmaceuticals, Inc. Announce Signing of Definitive Merger Agreement and SHANGHAI, China, September 12, 2018 Bison Capital Acquisition Corp. and Xynomic Pharmaceuticals, Inc. , a U.S.-China clinical stage innovative oncology drug development company, today jointly announced that they have signed a definitive merger agreement. Upon completion of the merger, Xynomic will become a wholly-owned subsidiary and the operating business of BCAC, and BCAC will change its name to “Xynomic Pharmaceuticals Holdings, Inc.” Xynomic, founded in 2016 by industry veterans and headquartered in the U.S. with operations in Raleigh, North Carolina and Shanghai, China, is principally engaged in the research, development and commercialization of innovative targeted can..." |
|
|
|